Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Murine transfer factor. III. Specific interactions between transfer factor and antigen.

C H Kirkpatrick, S J Rozzo, J J Mascali

    Journal of Immunology (Baltimore, Md. : 1950)
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2022
    Same author

    Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

    The British journal of dermatology·2021
    Same author

    Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2021
    Same author

    Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2020
    Same author

    Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.

    The Journal of dermatological treatment·2020
    Same author

    Outcomes of pregnancies from the tildrakizumab phase I-III clinical development programme.

    The British journal of dermatology·2020
    Same journal

    Crystal structure and immune single-cell atlas provide insights into the functional divergence of type I IFNs in fish.

    Journal of immunology (Baltimore, Md. : 1950)·2026
    Same journal

    Complement C3 deficiency increases the effector and cytotoxic functions of NK cells and suppresses tumor growth.

    Journal of immunology (Baltimore, Md. : 1950)·2026
    Same journal

    Increased Nur77 is disconnected from TCR affinity in insulin-specific Tregs.

    Journal of immunology (Baltimore, Md. : 1950)·2026
    Same journal

    FTR85 negatively regulates type I IFN antiviral signaling pathway by promoting K48-linked polyubiquitination of IRF3.

    Journal of immunology (Baltimore, Md. : 1950)·2026
    Same journal

    An MR1-specific nanobody capable of blocking MR1T cell activation.

    Journal of immunology (Baltimore, Md. : 1950)·2026
    Same journal

    TGF-β controls developmental fate and functional identity of thymic γδ T cells.

    Journal of immunology (Baltimore, Md. : 1950)·2026
    See all related articles

    Researchers studied interactions between transfer factor and antigens. Specific transfer factor activity was removed by antigen-coated surfaces, indicating a molecular basis for immune specificity.

    Area of Science:

    • Immunology
    • Molecular Biology

    Background:

    • Transfer factor (TF) mediates cellular immunity.
    • The molecular basis for TF specificity remains incompletely understood.

    Purpose of the Study:

    • To investigate the molecular interactions between transfer factor and specific antigens.
    • To provide evidence for a molecular basis of TF specificity.

    Main Methods:

    • Incubation of TF-containing dialysates with antigen-coated surfaces (ferritin or cytochrome c).
    • Assessing antigen-sensitizing activity before and after incubation.
    • Elution of specific TF activity using urea or acetonitrile.

    Main Results:

    • TF activity was specifically removed by antigen-coated surfaces corresponding to the TF's sensitization.

    Related Experiment Videos

  • Incubation with non-matching antigen-coated surfaces did not remove TF activity.
  • Specific TF activities were successfully recovered using elution agents.

    • Conclusions:

    • Direct molecular interactions occur between transfer factor and specific antigens.
    • These interactions provide evidence for the molecular basis of TF's immunologic specificity.
    • The described method may facilitate the isolation of specific TF for chemical analysis.